ARDS, Coagulation, COVID-19, Hemostasis, Pneumonia
Conditions
Keywords
COVID-19, pneumonia, ARDS, venous ultrasound, hemostasis, coagulation
Brief summary
The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components. Elements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of pro-inflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation-induced thrombosis. Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. Very few data are available regarding the biological disorders of coagulation in these patients. Th purpose of this project is to analyze hemostasis and coagulation of patients with infection of COVID-19 and severe pneumonia.
Interventions
OTHERvenous ultrasound
Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
OTHERblood sample
blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients hospitalized in medical ICU with pneumonia due to COVID-19 infection
Exclusion criteria
* patients\< 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation of thrombin time (in secondes) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds) |
| Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. |
| Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU. |
| Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU. | up to 6 weeks | Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU. |
Countries
France
Outcome results
None listed